Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$81,365.00-0.12%ETH$2,399.97+0.22%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMDX

Insight Molecular Diagnostics Inc.

Healthcare · Biotechnology

$2.84

Down-$0.01 (-0.35%)

Updated Oct 23, 2026, 8:39 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
149.63M
P/E ratio
-0.03
Dividend yield
0.00%
52-week range
$2.42 – $6.86
Volume
262.01K
Avg. volume
70.5K

Price performance · IMDX

IMDX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 22, 2026

IMDX closed at $2.84 after 21 trading sessions, down 28.10% for the selected period.

Last close
$2.84
Period change
-28.10%
Period low
$2.79
Period high
$3.95
Daily close
View OHLC price history
IMDX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 22, 2026$2.94$2.99$2.75$2.84262.01K
Oct 21, 2026$3.04$3.10$2.89$3.02300.29K
Oct 20, 2026$2.96$3.275$2.96$3.03316.1K
Oct 19, 2026$3.01$3.025$2.78$2.89474.15K
Oct 16, 2026$3.07$3.18$2.89$3.01181.5K
Oct 15, 2026$2.81$3.12$2.79$3.06177.68K
Oct 14, 2026$2.98$3.10$2.75$2.79407.55K
Oct 13, 2026$3.16$3.20$2.9425$2.99313.5K
Oct 12, 2026$3.35$3.37$3.13$3.17219.52K
Oct 9, 2026$3.29$3.441$3.19$3.37156.36K
Oct 8, 2026$3.44$3.56$3.08$3.28227.32K
Oct 7, 2026$3.35$3.665$3.26$3.46153.87K
Oct 6, 2026$3.73$3.7566$3.19$3.38460.09K
Oct 5, 2026$3.44$3.74$3.17$3.67408.37K
Oct 2, 2026$3.49$3.60$3.36$3.44403.02K
Oct 1, 2026$3.57$3.625$3.24$3.47395.2K
Sep 30, 2026$3.40$3.665$3.31$3.59287.13K
Sep 29, 2026$3.23$3.5049$3.07$3.38311.22K
Sep 28, 2026$3.82$3.99$3.15$3.18590.53K
Sep 25, 2026$3.99$4.002$3.76$3.92313.5K
Sep 24, 2026$3.88$4.00$3.70$3.95274.27K

Latest IMDX news

The latest Smart Investors Daily articles mentioning IMDX.

Stock researchCompany · Overview

IMDX research

Overview

Company profile and research snapshot.

Company profile

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
IMDX recent ratings
DateFirmRatingTarget
Aug 24, 2026LUCID CAPITAL MARKETSBuy—
Aug 18, 2026NeedhamBuy—
Feb 17, 2026Lake StreetBuy—
Nov 11, 2025NeedhamBuy—
Aug 18, 2025NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 14, 2026

iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

NASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced the appointment of Donnie Purto as Senior Vice President of Sales to lead the company’s commercialization efforts as it prepares to bring GraftAssureDx to market. GraftAssureDx is currently under FDA medical device review and is awaiting regulatory authorization. Mr. Purto is an accomplished sales leader with more than 20 years of experience building and leading high-performin

Yahoo · Oct 12, 2026

iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings

NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health Forum, which will include a key opinion leader (KOL) virtual discussion and one-on-one meetings between investors and management. The KOL discussion will feature iMDx CEO Josh Riggs, as well as Prof. Dr. Med. Klemens Budde, who is a kidney transplantation researcher and a head of the

Yahoo · Sep 2, 2026

iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference

NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference taking place September 10th, 2026 in New York. Event: Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” ConferenceWho: Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea JamesDate: Thursday, September 10, 2026Location: Metropolit

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By